Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1913-1920

  Haider, Asifa S ^a   Lowes, Michelle A ^a   Suárez Fariñas, Mayte ^a   Zaba, Lisa C ^a   Cardinale, Irma ^a   Khatcherian, Artemis ^a   Novitskaya, Inna ^a   Wittkowski, Knut M ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN P40; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; CD3 ANTIGEN; CD83 ANTIGEN; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NOS2A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ACTIVITY; DOWN REGULATION; GENE ACTIVITY; GENE CONSTRUCT; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INFLAMMATION; MICROARRAY ANALYSIS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HELPER CELL; IMMUNOLOGY; PATHOLOGY; PHARMACOGENETICS; PSORIASIS; SIGNAL TRANSDUCTION; SKIN;

ANTIGENS, CD; ANTIGENS, CD3; AUTOIMMUNE DISEASES; CYCLOSPORINE; DENDRITIC CELLS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MEMBRANE GLYCOPROTEINS; NITRIC OXIDE SYNTHASE TYPE II; PHARMACOGENETICS; PSORIASIS; SIGNAL TRANSDUCTION; SKIN; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40749156754     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1913     Document Type: Article

References (46)

1. Bowcock, A. M., and J. G. Krueger. 2005. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. 5: 699-711.
2. Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
3. Lew, W., A. M. Bowcock, and J. G. Krueger. 2004. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "type 1" inflammatory gene expression. Trends Immunol. 25: 295-305.
4. Austin, L. M., M. Ozawa, T. Kikuchi, I. B. Walters, and J. G. Krueger. 1999. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759.
5. Shen, F., Z. Hu, J. Goswami, and S. L. Gaffen. 2006. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281: 24138-24148.
6. Shen, F., M. J. Ruddy, P. Plamondon, and S. L. Gaffen. 2005. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. J. Leukocyte Biol. 77: 388-399.
7. Moseley, T. A., D. R. Haudenschild, L. Rose, and A. H. Reddi. 2003. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14: 155-174.
8. Li, J., D. Li, and Z. Tan. 2004. The expression of interleukin-17, interferon-γ, and macrophage inflammatory protein-3 α mRNA in patients with psoriasis vulgaris. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24: 294-296.
9. Liu, X. K., J. L. Clements, and S. L. Gaffen. 2005. Signaling through the murine T cell receptor induces IL-17 production in the absence of costimulation, IL-23 or dendritic cells. Mol. Cells 20: 339-347.
10. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25: 821-852.
11. Homey, B., M. C. Dieu-Nosjean, A. Wiesenborn, C. Massacrier, J. J. Pin, E. Oldham, D. Catron, M. E. Buchanan, A. Muller, R. DeWaal Malefyt, et al. 2000. Up-regulation of macrophage inflammatory protein-3 α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164: 6621-6632.
12. Zheng, Y., D. M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2007. Interleukin-22, a Th17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
13. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646.
14. Borel, J. F., C. Feurer, H. U. Gubler, and H. Stahelin. 1976. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468-475.
15. Schreiber, S. L., and G. R. Crabtree. 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13: 136-142.
16. Ellis, C. N., D. C. Gorsulowsky, T. A. Hamilton, J. K. Billings, M. D. Brown, J. T. Headington, K. D. Cooper, O. Baadsgaard, E. A. Duell, T. M. Annesley, et al. 1986. Cyclosporine improves psoriasis in a double-blind study. J. Am. Med. Assoc. 256: 3110-3116.
17. Gottlieb, A. B., J. G. Krueger, L. Khandke, R. M. Grossman, J. Krane, and D. M. Carter. 1991. Role of T cell activation in the pathogenesis of psoriasis. Ann. NY Acad. Sci. 636: 377-379.
18. Gupta, A. K., O. Baadsgaard, C. N. Ellis, J. J. Voorhees, and K. D. Cooper. 1989. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch. Dermatol. Res. 281: 219-226.
19. Tada, Y., A. Asahina, T. Takekoshi, E. Kishimoto, H. Mitsui, H. Saeki, M. Komine, and K. Tamaki. 2006. Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A. Br. J. Dermatol. 154: 1180-1183.
20. Liu, Y., J. G. Krueger, and A. M. Bowcock. 2007. Psoriasis: genetic associations and immune system changes. Genes Immun. 8: 1-12.
21. Haider, A. S., M. A. Lowes, M. Suarez-Farinas, L. C. Zaba, I. Cardinale, M. Blumenberg, and J. G. Krueger. 2007. Cellular genomic maps help dissect pathology in human skin disease. J. Invest. Dermatol. In press.
22. Nakae, S., Y. Iwakura, H. Suto, and S. J. Galli. 2007. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukocyte Biol. 81: 1258-1268.
23. Lowes, M. A., F. Chamian, M. V. Abello, J. Fuentes-Duculan, S. L. Lin, R. Nussbaum, I. Novitskaya, H. Carbonaro, I. Cardinale, T. Kikuchi, et al. 2005. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA 102: 19057-19062.
24. Romanowska, M., N. Al Yacoub, H. Seidel, S. Donandt, H. Gerken, S. Phillip, N. Haritonova, M. Artuc, S. Schweiger, W. Sterry, and J. Foerster. 2007. PPARδ enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J. Invest. Dermatol. In press.
25. Chamian, F., M. A. Lowes, S. L. Lin, E. Lee, T. Kikuchi, P. Gilleaudeau, M. Sullivan-Whalen, I. Cardinale, A. Khatcherian, I. Novitskaya, et al. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102: 2075-2080.
26. Haider, A. S., S. B. Peters, H. Kaporis, I. Cardinale, J. Fei, J. Ott, M. Blumenberg, A. M. Bowcock, J. G. Krueger, and J. A. Carucci. 2006. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J. Invest. Dermatol. 126: 869-881.
27. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3: Article 3.
28. Albert, J. M. 1999. A threshold causal model for clinical trials with departures from intended treatment. Stat. Med. 18: 1615-1626.
29. Cnaan, A., N. M. Laird, and P. Slasor. 1997. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat. Med. 16: 2349-2380.
30. Wolk, K., E. Witte, E. Wallace, W. D. Docke, S. Kunz, K. Asadullah, H. D. Volk, W. Sterry, and R. Sabat. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36: 1309-1323.
31. Teunissen, M. B., C. W. Koomen, R. de Waal Malefyt, E. A. Wierenga, and J. D. Bos. 1998. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111: 645-649.
32. Gottlieb, A. B., K. D. Cooper, T. S. McCormick, E. Toichi, D. E. Everitt, B. Frederick, Y. Zhu, C. E. Pendley, M. A. Graham, and M. A. Mascelli. 2007. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23: 1081-1092.
33. Gottlieb, A. B., F. Chamian, S. Masud, I. Cardinale, M. V. Abello, M. A. Lowes, F. Chen, M. Magliocco, and J. G. Krueger. 2005. TNF inhibition rapidly downregulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175: 2721-2729.
34. Liang, S. C., X. Y. Tan, D. P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, M. Collins, and L. A. Fouser. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203: 2271-2279.
35. Oestreicher, J. L., I. B. Walters, T. Kikuchi, P. Gilleaudeau, J. Surette, U. Schwertschlag, A. J. Dorner, J. G. Krueger, and W. L. Trepicchio. 2001. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 1: 272-287.
36. Trepicchio, W. L., M. Ozawa, I. B. Walters, T. Kikuchi, P. Gilleaudeau, J. L. Bliss, U. Schwertschlag, A. J. Dorner, and J. G. Krueger. 1999. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104: 1527-1537.
37. Lee, E., W. L. Trepicchio, J. L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130.
38. Tajima, K., R. Amakawa, T. Ito, M. Miyaji, M. Takebayashi, and S. Fukuhara. 2003. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 108: 321-328.
39. Stary, G., C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204: 1441-1451.
40. + myeloid-derived cells in psoriasis: gene regulation and cellular effects. J. Invest. Dermatol. 126: 1590-1599.
41. Romer, J., E. Hasselager, P. L. Norby, T. Steiniche, J. Thorn Clausen, and K. Kragballe. 2003. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. 121: 1306-1311.
42. Flier, J., D. M. Boorsma, P. J. van Beek, C. Nieboer, T. J. Stoof, R. Willemze, and C. P. Tensen. 2001. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J. Pathol. 194: 398-405.
43. Schmuth, M., S. Neyer, C. Rainer, A. Grassegger, P. Fritsch, N. Romani, and C. Heufler. 2002. Expression of the C-C chemokine MIP-3 α/CCL20 in human epidermis with impaired permeability barrier function. Exp. Dermatol. 11: 135-142.
44. Baker, B. S., A. F. Swain, H. Valdimarsson, and L. Fry. 1984. T-cell subpopulations in the blood and skin of patients with psoriasis. Br. J. Dermatol. 110: 37-44.
45. Petrik, J. 2001. Microarray technology: the future of blood testing? Vox Sang. 80: 1-11.
46. Wittkowski, K. M. E. Lee, R. Nussbaum, F. N. Chamian, and J. G. Krueger. 2004. Combining several ordinal measures in clinical studies. Stat. Med. 23: 1579-1592.